Floatz logo

LEUPROLIDE

HER2-positive Advanced Breast Cancer

Fudan Universityprotein_peptidePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the HER2-positive Advanced Breast Cancer cohort.

Asset / SponsorPhaseRating
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB
Inetetamab
Fudan University
Phase 2/3B
TQB2930 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3B
bat8001
Bio-Thera Solutions
Phase 3B
Calcium folinate pentahydrate
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1CC

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →